Online Inquiry
Inquiry
JNJ-7706621
| Product Name: | JNJ-7706621 |
| CAT#: | DEAK-2312-LGZ-6 |
| Package: | 5mg/10mg/50mg/100mg/10mM * 1mL in DMSO |
| Datasheet |
Description
JNJ-7706621 is a pan-CDK inhibitor with the highest potency against CDK1/2, with an IC50 of 9 nM/4 nM. Its selectivity for CDK1/2 is 6 times higher than CDK3/4/6 in cell-free assays. It also effectively inhibits Aurora A/B and is inactive against Plk1 and Wee1.
Basic Information
| Synonyms: | JNJ7706621 |
| Application: | CDK/Aurora A/B Inhibitor |
| CAS Number: | 443797-96-4 |
| Formula: | C15H12F2N6O3S |
| Molecular Weight: | 394.4 |
| SMILES: | C1=CC(=C(C(=C1)F)C(=O)N2C(=NC(=N2)NC3=CC=C(C=C3)S(=O)(=O)N)N)F |
| Solubility-In vitro: | In vitro (25°C): DMSO: 67 mg/mL (169.89 mM) Water: Insoluble Ethanol: Insoluble |
| Solubility-In vivo: | 0.5% methylcellulose+0.2% Tween 80: 13 mg/mL |
Target Info
| CDK6/cyclinD1: | 175 nM (IC50) |
| CDK2/cyclinE: | 3 nM (IC50) |
| Cdk4/cyclin D1: | 253 nM (IC50) |
| Cdk1/cyclin B: | 9 nM (IC50) |
| cdk2/cyclin A: | 4 nM (IC50) |
| CDK3/Cyclin E: | 58 nM (IC50) |
| Aurora A: | 11 nM (IC50) |
| Aurora B: | 15 nM (IC50) |
| VEGF-R2: | 154 nM (IC50) |
| VEGF-R1: | 6400 nM (IC50) |
| VEGF-R3: | 735 nM (IC50) |
| FGF-R1: | 575 nM (IC50) |
| FGF-R2: | 226 nM (IC50) |
| GSK3β: | 254 nM (IC50) |
Storage
|
Preparing Stock Solutions
|
0.1 mM_1 mg: 25.35 mL
0.1 mM_5 mg: 126.77 mL
0.1 mM_10 mg: 253.55 mL
0.5 mM_1 mg: 5.07 mL
0.5 mM_5 mg: 25.35 mL
0.5 mM_10 mg: 50.71 mL
1 mM_1 mg: 2.54 mL
1 mM_5 mg: 12.68 mL
1 mM_10 mg: 25.35 mL
5 mM_1 mg: 0.51 mL
5 mM_5 mg: 2.54 mL
5 mM_10 mg: 5.07 mL
|
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
